254 Results
Biodesix will release financial results for the third quarter before the open of trading on November 3. Biodesix’s will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. ET.
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio.
Biodesix Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio
Biodesix expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 202, reflecting continued growth in the Company’s core lung diagnostic testing.
Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference
Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.
Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.
Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.
